Zalecenia Polskiego Towarzystwa Ginekologii Onkologicznej dotyczące diagnostyki i leczenia raka jajnika

• Autorzy: Antoni Basta , Mariusz Bidziński , Andrzej Bieńkiewicz , Paweł Blecharz , Lubomir Bodnar , Robert Jach , Paweł Knapp , Zbigniew Kojs , Jan Kotarski , Janina Markowska , Marcin Misiek , Jacek Jan Sznurkowski , Łukasz Wicherek , Włodzimierz Sawicki , Agnieszka Timorek-Lemieszczuk , Jan Bahyrycz , Radosław Mądry

Warianty tytułu

EN

Recommendations of the Polish Gynecological Oncology Society for the diagnosis and treatment of ovarian cancer

• Języki publikacji: EN PL

Abstrakty

EN

Over 95% of ovarian malignancies arise from the epithelium. The major risk factors for ovarian cancer include: • hereditary mutation of BRCA1 and BRCA2 genes (16–20% of all ovarian cancers); • hereditary breast and ovarian cancer syndrome; • familial history of hereditary nonpolyposis colorectal cancer (HNPCC) (Lynch syndrome – nonpolyposis colorectal cancer, endometrial cancer, cancer of the upper gastrointestinal tract, ureteral cancer); • infertility, long-term stimulation of ovulation, unsuccessful IVF (in vitro fertilisation) attempts; • hormone replacement therapy. Factors that decrease the risk for ovarian cancer include oral contraceptive use, tubal ligation, salpingo-oophorectomy, hysterectomy and breastfeeding(1).

PL

Ponad 95% nowotworów złośliwych jajnika ma pochodzenie nabłonkowe. Do najważniejszych czynników ryzyka występowania raka jajnika należą: • nosicielstwo mutacji genów BRCA1 i BRCA2 (dotyczy do 16–20% wszystkich przypadków raka jajnika); • zespoły dziedzicznego raka piersi i jajnika; • rodzinne występowanie dziedzicznego niepolipowatego raka jelita grubego (zespół Lyncha – niepolipowaty rak jelita grubego, rak endometrium, rak górnego odcinka układu pokarmowego, rak urotelialny moczowodu); • bezdzietność, długotrwała stymulacja owulacji, nieskuteczne próby IVF (in vitro fertilisation – zapłodnienie pozaustrojowe, zapłodnienie in vitro); • hormonalna terapia zastępcza. Ryzyko wystąpienia raka jajnika zmniejszają: stosowanie antykoncepcji hormonalnej, okluzja jajowodów, wycięcie jajników i jajowodów, wycięcie macicy i karmienie piersią(1).

• Czasopismo: Current Gynecologic Oncology
• Rocznik: 2017
• Tom: 15
• Numer: 1
• Strony: 5-23

Twórcy

autor

Antoni Basta

autor

Mariusz Bidziński

autor

Andrzej Bieńkiewicz

autor

Paweł Blecharz

autor

Lubomir Bodnar

autor

Robert Jach

autor

Paweł Knapp

autor

Zbigniew Kojs

autor

Jan Kotarski

autor

Janina Markowska

autor

Marcin Misiek

autor

Jacek Jan Sznurkowski

autor

Łukasz Wicherek

autor

Włodzimierz Sawicki

autor

Agnieszka Timorek-Lemieszczuk

autor

Jan Bahyrycz

autor

Radosław Mądry

• Uniwersytet Medyczny Poznań,

Bibliografia

• 1. Schorge JO, Modesitt SC, Coleman RL et al.: SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol 2010; 119: 7–17.
• 2. Smith RA, Manassaram-Baptiste D, Brooks D et al.: Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening. CA Cancer J Clin 2015; 65: 30–54.
• 3. Rosenthal AN, Fraser L, Philpott S et al.: Final results of 4-monthly screening in the UK Familial Ovarian Cancer Screening Study (UKFOCSS Phase 2). J Clin Oncol 2013; 31 (Suppl): abstract 5507.
• 4. Kauff ND, Satagopan JM, Robson ME et al.: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609–1615.
• 5. McAlpine JN, Hanley GE, Woo MM et al.; Ovarian Cancer Research Program of British Columbia: Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol 2014; 210: 471.e1–471.e11.
• 6. Kamran MW, Vaughan D, Crosby D et al.: Opportunistic and interventional salpingectomy in women at risk: a strategy for preventing pelvic serous cancer (PSC). Eur J Obstet Gynecol Reprod Biol 2013; 170: 251–254.
• 7. Yoon SH, Kim SN, Shim SH et al.: Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: a meta-analysis. Eur J Cancer 2016; 55: 38–46.
• 8. Goff BA, Mandel LS, Drescher CW et al.: Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007; 109: 221–227.
• 9. Geomini P, Kruitwagen R, Bremer GL et al.: The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol 2009; 113: 384–394.
• 10. Van Calster B, Van Hoorde K, Valentin L et al.; International Ovarian Tumour Analysis Group: Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. BMJ 2014; 349: g5920.
• 11. Vang R, Shih IeM, Kurman RJ: Ovarian low-grade and highgrade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009; 16: 267–282.
• 12. Ledermann J, Harter P, Gourley C et al.: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes byBRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15: 852–861.
• 13. Prat J; FIGO Committee on Gynecologic Oncology: Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014; 124: 1–5.
• 14. Schorge JO, Eisenhauer EE, Chi DS: Current surgical management of ovarian cancer. Hematol Oncol Clin North Am 2012; 26: 93–109.
• 15. Cheng A, Li M, Kanis MJ et al.: Is it necessary to perform routine appendectomy for mucinous ovarian neoplasms? A retrospective study and meta-analysis. Gynecol Oncol 2017; 144: 215–222.
• 16. Morice P, Denschlag D, Rodolakis A et al.; Fertility Task Force of the European Society of Gynecologic Oncology: Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors. Int J Gynecol Cancer 2011; 21: 951–963.
• 17. Satoh T, Hatae M, Watanabe Y et al.: Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. J Clin Oncol 2010; 28: 1727–1732.
• 18. Fagotti A, Vizzielli G, De Iaco P et al.: A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. Am J Obstet Gynecol 2013; 209: 462.e1–462.e11.
• 19. Elattar A, Bryant A, Winter-Roach BA et al.: Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2011; (8): CD007565.
• 20. Harter P, Sehouli J, Lorusso D et al.: LION: Lymphadenectomy in ovarian neoplasms – a prospective randomized AGO study group led gynecologic cancer intergroup trial. J Clin Oncol 2017; 35 (suppl; abstr 5500).
• 21. Morrison J, Haldar K, Kehoe S et al.: Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev 2012; (8): CD005343.
• 22. da Costa Miranda V, de Souza Fêde ÂB, Dos Anjos CH et al.: Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: safety and effectiveness. Gynecol Oncol 2014; 132: 287–291.
• 23. Bookman MA, Brady MF, McGuire WP et al.: Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009; 27: 1419–1425.
• 24. Ozols RF, Bundy BN, Greer BE et al.; Gynecologic Oncology Group: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194–3200.
• 25. McGuire WP, Hoskins WJ, Brady MF et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1–6.
• 26. Armstrong DK, Bundy B, Wenzel L et al.; Gynecologic Oncology Group: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34–43.
• 27. Walker JL, Brady MF, DiSilvestro PA et al.: A phase III clinical trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube and primary peritoneal carcinoma. NCI-supplied agent(s): bevacizumab (NSC #704865, IND #7921). NCT01167712 a GOG/NRG trial (GOG 252). Presented at: 2016 SGO Annual Meeting. March 19–22, 2016. San Diego, CA. Latebreaking abstract.
• 28. Katsumata N, Yasuda M, Isonishi S et al.; Japanese Gynecologic Oncology Group: Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 2013; 14: 1020–1026.
• 29. Pignata S, Scambia G, Katsaros D et al.; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators: Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2014; 15: 396–405.
• 30. Oza AM, Cook AD, Pfisterer J et al.; ICON7 trial investigators: Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 2015; 16: 928–936.
• 31. Vasey PA, Paul J, Birt A et al.: Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group. J Clin Oncol 1999; 17: 2069–2080.
• 32. Bell J, Brady MF, Young RC et al.; Gynecologic Oncology Group: Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006; 102: 432–439.
• 33. Vergote I, Tropé CG, Amant F et al.; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943–953.
• 34. Kehoe S, Hook J, Nankivell M et al.: Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, noninferiority trial. Lancet 2015; 386: 249–257.
• 35. Rouzier R, Gouy S, Selle F et al.: Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: results from the ANTHALYA trial. Eur J Cancer 2017; 70: 133–142.
• 36. Copeland LJ, Brady MF, Burger RA et al.: Phase III trial of maintenance therapy in women with advanced ovary/tubal/peritoneal cancer after a complete response to first-line therapy: an NRG oncology (GOG Legacy) study. Presented at: 2017 SGO Annual Meeting; March 12–15, 2017; National Harbor, MD. Abstract LBA1.
• 37. Rustin GJ, van der Burg ME, Griffin CL et al.; MRC OV05; EORTC 55955 investigators: Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010; 376: 1155–1163.
• 38. Du Bois A, Vergote I, Ferron G et al.; Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol 2017; 35 (suppl; abstr 5501).
• 39. Friedlander M, Trimble E, Tinker A et al.; Gynecologic Cancer InterGroup: Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer 2011; 21: 771–775.
• 40. du Bois A, Reuss A, Pujade-Lauraine E et al.: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 2009; 115: 1234–1244.
• 41. Kristeleit RS, Shapira-Frommer R, Oaknin A et al.: Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2). Presented at: 2016 ESMO Congress; October 7–11, 2016; Copenhagen, Denmark. Abstract 8560.
• 42. Kaufman B, Shapira-Frommer R, Schmutzler RK et al.: Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015; 33: 244–250.
• 43. Gordon AN, Fleagle JT, Guthrie D et al.: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312–3322.
• 44. ten Bokkel Huinink W, Gore M, Carmichael J et al.: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183–2193.
• 45. Mutch DG, Orlando M, Goss T et al.: Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007; 25: 2811–2818.
• 46. Ferrandina G, Ludovisi M, Lorusso D et al.: Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008; 26: 890–896.
• 47. Gynecologic Oncology Group; Markman M, Blessing J, Rubin SC et al.: Phase II trial of weekly paclitaxel (80 mg/m2 ) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2006; 101: 436–440.
• 48. Pujade-Lauraine E, Hilpert F, Weber B et al.: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014; 32: 1302–1308.
• 49. Parmar MK, Ledermann JA, Colombo N et al.; ICON and AGO Collaborators: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099–2106.
• 50. Pfisterer J, Plante M, Vergote I et al.; AGO-OVAR; NCIC CTG; EORTC GCG: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24: 4699–4707.
• 51. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al.: Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010; 28: 3323–3329.
• 52. Aghajanian C, Blank SV, Goff BA et al.: OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30: 2039–2045.
• 53. Coleman RL, Brady MF, Herzog TJ et al.: Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017; 18: 779–791.
• 54. Ledermann J, Harter P, Gourley C et al.: Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382–1392.
• 55. Pujade-Lauraine E, Ledermann JA, Penson RT et al.: Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Annual Meeting on Women’s Cancer of the Society of Gynecologic Oncology; National Harbor, MD; March 12–15, 2017. Abstract LBA2.
• 56. Mirza MR, Monk BJ, Herrstedt J et al.; ENGOT-OV16/NOVA Investigators: Niraparib maintenance therapy in platinumsensitive, recurrent ovarian cancer. N Engl J Med 2016; 375: 2154–2164.
• 57. Gershenson DM, Bodurka DC, Coleman RL et al.: Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin Oncol 2017; 35: 1103–1111.
• 58. Tavassoli FA, Devilee P (eds.): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press, Lyon 2003.
• 59. Morice P, Uzan C, Fauvet R et al.: Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol 2012; 13: e103–e115.
• 60. Trillsch F, Mahner S, Woelber L et al.: Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. Ann Oncol 2014; 25: 1320–1327.
• 61. Vasconcelos I, Olschewski J, Braicu I et al.: A meta-analysis on the impact of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors with invasive implants. Oncologist 2015; 20: 151–158.
• 62. Faluyi O, Mackean M, Gourley C et al.: Interventions for the treatment of borderline ovarian tumours. Cochrane Database Syst Rev 2010; (9): CD007696.

• Typ dokumentu: article